Breaking News Instant updates and real-time market news.

TROV

Trovagene

$0.81

-0.0216 (-2.61%)

, AZN

AstraZeneca

$34.17

-0.65 (-1.87%)

08:04
06/12/17
06/12
08:04
06/12/17
08:04

Trovagene enters agreement with AstraZeneca in prospective biomarker study

Trovagene (TROV) announced it has entered into an agreement with AstraZeneca (AZN) to provide Trovera urine ctDNA biomarker test and services. The Trovera EGFR urine liquid biopsy test will initially be used in an open label prospective biomarker study evaluating whether the combined use of noninvasive testing is as effective as tissue testing in identifying epidermal growth factor receptor T790M mutation status.

TROV

Trovagene

$0.81

-0.0216 (-2.61%)

AZN

AstraZeneca

$34.17

-0.65 (-1.87%)

  • 15

    Jun

  • 26

    Jun

TROV Trovagene
$0.81

-0.0216 (-2.61%)

04/12/17
MAXM
04/12/17
UPGRADE
Target $4
MAXM
Buy
Maxim upgrades Trovagene back to Buy with $4 target
Maxim analyst Jason McCarthy upgraded Trovagene to Buy intraday after downgrading the stock to Hold on March 16. In-licensing a small molecule oncology drug from Nerviano Medical Sciences marks a new chapter for the company in precision cancer therapeutics, McCarthy tells investors in a research note. The analyst set a $4 price target for the shares. Trovagene in midday trading is up 15% to 87c.
04/12/17
MAXM
04/12/17
UPGRADE
Target $4
MAXM
Buy
Trovagene upgraded to Buy from Hold at Maxim
Maxim analyst Jason Kolbert upgraded Trovagene to Buy with a $4 price target. The analyst downgraded the shares to Hold on Marhc 16.
03/16/17
MAXM
03/16/17
DOWNGRADE
MAXM
Hold
Trovagene downgraded to Hold from Buy at Maxim
Maxim analyst Jason Kolbert downgraded Trovagene to Hold from Buy, saying he will need to re-evaluate the company given its newly announced strategic direction to focus on developing diagnostic-based therapeutics. Piper Jaffray analyst William Quirk also downgraded Trovagene to Underweight this morning.
03/16/17
PIPR
03/16/17
DOWNGRADE
Target $0.5
PIPR
Underweight
Trovagene downgraded to Underweight from Neutral at Piper Jaffray
Piper Jaffray analyst William Quirk downgraded Trovagene to Underweight citing an uncertain commercial strategy amid the company's shifts from liquid biopsy to collection devices to therapeutics. He cut his price target for the shares to 50c from $1.70 following Trovagene's Q4 results.
AZN AstraZeneca
$34.17

-0.65 (-1.87%)

06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
06/05/17
PIPR
06/05/17
NO CHANGE
PIPR
Piper views AstraZeneca, J&J as ASCO standouts
The standouts at ASCO over the weekend were the "compelling results" presented on Johnson & Johnson's (JNJ) Zytiga from the Latitude study in prostate cancer and AstraZeneca's (AZN) Lynparza in the OlympiAD trial in BRCA mutant breast cancer, Piper Jaffray analyst Richard Purkiss tells investors in a research note. In lung cancer, Merck's (MRK) updated data in KN021G "appears more promising" than Bristol-Myers' (BMY) updated data in CM012, the analyst adds. Purkiss believes, however, that relative to recent ASCOs, the data "so far in totality is underwhelming."
06/01/17
RHCO
06/01/17
NO CHANGE
RHCO
SunTrust sees $240/share takeout price for Tesaro
After the Wall Street Journal reported yesterday that Tesaro (TSRO) is exploring a sale, albeit with "modest" interest, SunTrust analyst Peter Lawson says his analysis suggests a $240 per share takeout price for the company. Tesaro closed yesterday up $5.88, or 4%, to $149.31. Acquisitions in the PARP inhibitor space are more likely to happen after Clovis Oncology's (CLVS) ARIEL 3 data at the end of June, as the readout will provide a more apples-to-apples comparison to Tesaro and AstraZeneca (AZN), Lawson tells investors in a research note. His "bull case" points to a $286 per share price for Tesaro and $92 per share price for Clovis. Lawson has Buy ratings on both names. JPMorgan's Cory Kasimov this morning said he likes the setup for Clovis shares into the late June data announcement.
05/17/17
JPMS
05/17/17
UPGRADE
Target $72
JPMS
Overweight
Clovis upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Cory Kasimov upgraded Clovis Oncology (CLVS) to Overweight and raised his price target for the shares to $72 from $58. The stock closed yesterday up 2%, or $1.05, to $49.56. The shares are down 35% over the last two months for "no clear fundamental reason," Kasimov tells investors in a research note. The analyst is "increasingly comfortable" recommending Clovis ahead of its Phase 3 study evaluating Rubraca in maintenance ovarian cancer now that more PARP class data has emerged. He has not seen "convincing evidence" that there is a clear efficacy difference between Clovis' rucaparib, Tesaro's (TSRO) niraparib and AstraZeneca's (AZN) olaparib.

TODAY'S FREE FLY STORIES

KMI

Kinder Morgan

$19.27

-0.5 (-2.53%)

13:50
09/21/17
09/21
13:50
09/21/17
13:50
Options
Kinder Morgan attracts call writers as shares slump »

Kinder Morgan attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBRY

BlackBerry

$9.85

0.71 (7.77%)

13:45
09/21/17
09/21
13:45
09/21/17
13:45
Options
BlackBerry call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

13:45
09/21/17
09/21
13:45
09/21/17
13:45
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

ICPT

Intercept

$98.12

1.92 (2.00%)

13:41
09/21/17
09/21
13:41
09/21/17
13:41
Hot Stocks
Breaking Hot Stocks news story on Intercept »

Intercept selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
09/21/17
09/21
13:40
09/21/17
13:40
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

HDSN

Hudson Technologies

$9.26

-0.03 (-0.32%)

13:39
09/21/17
09/21
13:39
09/21/17
13:39
Technical Analysis
Technical View: Hudson Technologies down on cautious Seeking Alpha mention »

The shares have taken a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

HDSN

Hudson Technologies

$9.26

-0.03 (-0.32%)

13:34
09/21/17
09/21
13:34
09/21/17
13:34
Periodicals
Hudson Technologies mentioned cautiously by Seeking Alpha contributor 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

OUT

Outfront Media

$21.19

-0.2 (-0.94%)

, LAMR

Lamar Advertising

$64.42

0.45 (0.70%)

13:30
09/21/17
09/21
13:30
09/21/17
13:30
Hot Stocks
Before the Move: Watch Outfront Media ahead of NYC-MTA contract decision »

A decision regarding the…

OUT

Outfront Media

$21.19

-0.2 (-0.94%)

LAMR

Lamar Advertising

$64.42

0.45 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

ILG

ILG

$25.87

0.56 (2.21%)

, VAC

Marriott Vacations

$119.30

5.31 (4.66%)

13:24
09/21/17
09/21
13:24
09/21/17
13:24
Periodicals
FrontFour plans ILG proxy fight if deal not struck this year, Bloomberg says »

FrontFour Capital, a…

ILG

ILG

$25.87

0.56 (2.21%)

VAC

Marriott Vacations

$119.30

5.31 (4.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

DDAIF

Daimler AG

$79.46

-0.16 (-0.20%)

, TSLA

Tesla

$373.91

-1.19 (-0.32%)

13:21
09/21/17
09/21
13:21
09/21/17
13:21
Hot Stocks
Mercedes-Benz to start production of electric passenger cars in U.S. »

Mercedes-Benz will set up…

DDAIF

Daimler AG

$79.46

-0.16 (-0.20%)

TSLA

Tesla

$373.91

-1.19 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

MSFT

Microsoft

$74.94

-0.5 (-0.66%)

13:20
09/21/17
09/21
13:20
09/21/17
13:20
Options
Notable call write in Microsoft »

Notable call write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 02

    Oct

  • 22

    Oct

$NSD

NASDAQ Market Internals

13:17
09/21/17
09/21
13:17
09/21/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
09/21/17
09/21
13:16
09/21/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
09/21/17
09/21
13:15
09/21/17
13:15
General news
Treasury's $11 B 10-year TIPS reopening was poorly received »

Treasury's $11 B…

XOP

SPDR Oil Exploration and Production Fund

$32.88

0.02 (0.06%)

13:10
09/21/17
09/21
13:10
09/21/17
13:10
Options
Hefty put spread in SPDR Oil and Gas Exploration ETF »

Hefty put spread in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIP

TripAdvisor

$43.92

0.32 (0.73%)

13:05
09/21/17
09/21
13:05
09/21/17
13:05
Options
TripAdvisor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:04
09/21/17
09/21
13:04
09/21/17
13:04
General news
10-Yr TIPS Auction Coupon Rate data reported »

10-Yr TIPS Auction Coupon…

13:04
09/21/17
09/21
13:04
09/21/17
13:04
General news
10-Yr TIPS Auction Total Amount data reported »

10-Yr TIPS Auction Total…

ZGNX

Zogenix

$13.60

-0.95 (-6.53%)

12:55
09/21/17
09/21
12:55
09/21/17
12:55
Options
Zogenix put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPXL

Impax

$21.55

0.6 (2.86%)

12:51
09/21/17
09/21
12:51
09/21/17
12:51
Periodicals
Impax merger with Amneal could come next month, WSJ reports »

Impax and Amneal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

CAR

Avis Budget

$37.92

1.28 (3.49%)

12:40
09/21/17
09/21
12:40
09/21/17
12:40
Options
Avis attracts a put buyer »

Avis attracts a put…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

12:40
09/21/17
09/21
12:40
09/21/17
12:40
General news
Treasury 10-year TIPS preview »

Treasury 10-year TIPS…

GIS

General Mills

$51.80

-0.3658 (-0.70%)

12:30
09/21/17
09/21
12:30
09/21/17
12:30
Options
Position adjustment in General Mills after earnings »

Position adjustment in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERIC

Ericsson

$5.60

-0.08 (-1.41%)

12:29
09/21/17
09/21
12:29
09/21/17
12:29
Upgrade
Ericsson rating change  »

Ericsson upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOK

Nokia

$6.09

-0.095 (-1.54%)

12:29
09/21/17
09/21
12:29
09/21/17
12:29
Downgrade
Nokia rating change  »

Nokia downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.